Trastuzumab Deruxtecan in Advanced Breast Cancer
NCT07180264 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 118
Last updated 2025-11-18
Summary
To evaluate the efficacy and safety of trastuzumab deruxtecan in advanced breast cancer patients.
Conditions
Interventions
- DRUG
-
Trastuzumab deruxtecan is a combination of the targeted cancer drug trastuzumab (also known as Herceptin) and a chemotherapy drug called deruxtecan or DXd.
Sponsors & Collaborators
-
Wenjin Yin
lead OTHER
Principal Investigators
-
Wenjin Yin, M.D. · Renji Hospital,School of Medicine, Shanghai Jiaotong University
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-08-28
- Primary Completion
- 2027-02-28
- Completion
- 2029-02-28
Countries
- China
Study Locations
More Related Trials
-
A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
NCT02131064 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer
NCT07246317 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Real-world Effectiveness and Safety Study of T-Dxd in Chinese Metastatic Breast Cancer
NCT05594082 ·Status: UNKNOWN
-
Dose-dense (Biweekly) Carboplatin Plus Paclitaxel With or Without Trastuzumab as Neoadjuvant Treatment for Breast Cancer
NCT02059876 ·Status: UNKNOWN ·Phase: PHASE2
-
To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical Study
NCT05656079 ·Status: UNKNOWN ·Phase: NA
-
BMS-214662 Plus Trastuzumab in Treating Patients With Advanced Solid Tumors
NCT00022529 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Herceptin (Trastuzumab) in Combination With a Taxane in Participants With HER2-Positive Breast Cancer Who Relapsed After (Neo)Adjuvant Herceptin Treatment
NCT01301729 ·Status: COMPLETED ·Phase: PHASE4
-
Short-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer
NCT05891561 ·Status: RECRUITING ·Phase: PHASE2
-
Chemotherapy for Elderly Patients Diagnosed With Localized HER2 Positive Breast Cancer
NCT02102438 ·Status: WITHDRAWN ·Phase: NA
-
Efficacy and Safety Study of Trastuzumab, Paclitaxel and Carboplatin on HER2+ Preoperative Breast Cancer
NCT01170143 ·Status: UNKNOWN ·Phase: PHASE2
-
Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients.
NCT03735966 ·Status: COMPLETED ·Phase: PHASE2
-
Neoadjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer
NCT04126525 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Neoadjuvant Study of Navelbine in Patients With HER2 Positive Breast Cancer
NCT04665986 ·Status: UNKNOWN ·Phase: PHASE3
-
A Multicenter Prospective Cohort Study of Adjuvant Therapy for BRCA1/2 Mutated Hormone Receptor-positive HER2-negative Early High-risk Breast Cancer
NCT06791161 ·Status: ENROLLING_BY_INVITATION
-
A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer
NCT01572038 ·Status: COMPLETED ·Phase: PHASE3
-
Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is Inoperable, Recurrent, or Metastatic
NCT00003440 ·Status: COMPLETED ·Phase: PHASE3
-
Neoadjuvant Study of Nab-paclitaxel Plus Carboplatin in Breast Cancer
NCT01625429 ·Status: UNKNOWN ·Phase: PHASE2
-
Risk Assessment Model of Trastuzumab-related Cardiotoxicity in Breast Cancer Patients
NCT04962425 ·Status: UNKNOWN
-
Feasibility Study of Metronomic Chemotherapy for Locally Advanced Her2- Positive Breast Cancer (TraQ-Me 01)
NCT01329640 ·Status: TERMINATED ·Phase: PHASE2
-
Trastuzumab Combined With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuvant Therapy
NCT04973319 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer
NCT00365365 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Adjuvant Docetaxel and Trastuzumab in Stage I HER2-positive Breast Cancer
NCT05189067 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Four Cycles Taxane With Trastuzumab and Pertuzumab Neoadjuvant Therapy Among Low Risk HER2 Positive Patients
NCT06722599 ·Status: RECRUITING
-
Randomized Trial With Trastuzumab Versus Observation in Breast Cancer Patients
NCT00429247 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
NCT01940497 ·Status: COMPLETED ·Phase: PHASE3